An Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of Danicamtiv on the Pharmacokinetics of Midazolam in Patients With Stable Heart Failure With Reduced Ejection Fraction
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Danicamtiv (Primary) ; Midazolam (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 03 Apr 2024 Status changed from recruiting to completed.
- 08 Sep 2023 Status changed from not yet recruiting to recruiting.
- 21 Jul 2023 New trial record